Kobe-Based M's Science To Accelerate Cerebral Infarction Clinical Drug Trials
This article was originally published in PharmAsia News
Executive SummaryKobe-based clinical stage drug discovery and development venture company, M's Science, announced the allocation of new shares to a third party May 26 in an effort to speed up clinical trials for SA4503. Developed by the company, SA4503 is a drug agent with potential applications for treating cerebral infarction and depression, and currently it is in Phase II trials in Europe. The ¥940 million investment infusion comes from 16 venture capital companies, including Japan Asia Investment Corp, Yasuda Enterprise Development and First Track Initiative. The funds will be used to speed up the trials. (Click here for more - Japanese language
You may also be interested in...
Biologic Exclusivity Provisions In USMCA Are Boon To Generics Industry; BIO Is 'Tremendously Worried'
Revised North American trade deal touted as enabling Congress to address crisis of high drug prices; requirement for 10 years biologic exclusivity is removed and language to allow incentives for generics added.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.